Results of Clinical Trials, New Drug Applications, Leadership Appointments, and Scheduled Earnings - Research Reports on Biogen, Salix, Express Scripts, Stryker and Shire

NEW YORK, September 23, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Biogen Idec Inc. (NASDAQ: BIIB), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Express Scripts Holding Company (NASDAQ: ESRX), Stryker Corporation (NYSE: SYK) and Shire plc. (NASDAQ: SHPG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6674-100free.

--
Biogen Idec Inc. Research Reports
On September 12, 2014, Biogen Idec Inc. (Biogen), along with AbbVie, announced the full results from the Phase 3 DECIDE clinical trial, which showed that compared to AVONEX® (interferon beta-1a), ZINBRYTA™ (daclizumab high-yield process), dosed subcutaneously once a month, demonstrated a statistically significant improvement in reducing disease activity in people with relapsing-remitting multiple sclerosis (RRMS). Biogen stated that DECIDE was a two- to three-year, Phase 3, global, randomized, double-blind study which evaluated if ZINBRYTA would provide superior outcomes for certain clinical endpoints compared to AVONEX. Ludwig Kappos, M.D., Chair, Department of Neurology and Head, MS-Research Group, University Hospital, Basel, Switzerland, and lead investigator for DECIDE said, "These results help us better understand ZINBRYTA as a potential treatment option for people with relapsing-remitting MS." The full research reports on Biogen are available to download free of charge at:

http://www.analystsreview.com/Sep-23-2014/BIIB/report.pdf

--
Salix Pharmaceuticals Ltd. Research Reports
On September 18, 2014, Salix Pharmaceuticals Ltd. (Salix) announced that the Company's August 29, 2014 resubmission of its supplemental New Drug Application (sNDA) for XIFAXAN® 550 mg tablets for the proposed indication of the treatment of irritable bowel syndrome with diarrhea (IBS-D) is considered to be complete by the Food and Drug Administration (FDA). Salix informed that the resubmission has been assigned a user fee goal date of February 28, 2015. Salix added that the result of XIFAXAN 550mg TARGET 3 Study was selected by American College of Gastroenterology for an Oral Presentation to be held on October 21, 2014 at the college's 2014 Annual Scientific Meeting. "We believe the efficacy and safety data collected in TARGET 1, TARGET 2 and TARGET 3 comprise a compelling data set that should provide adequate information for the basis of the product labeling used to guide patients and their health care providers on how to safely and most effectively administer rifaximin to treat patients with IBS-D," stated Bill Forbes, PharmD, Executive Vice President, Medical, Research and Development and Chief Development Officer, Salix. The full research reports on Salix are available to download free of charge at:

http://www.analystsreview.com/Sep-23-2014/SLXP/report.pdf

--
Express Scripts Holding Company Research Reports
On September 12, 2014, Express Scripts Holding Company (Express Scripts) announced the appointment of Roderick Palmore to its Board of Directors as a member of the corporate governance committee. According to Express Scripts, Mr. Palmore serves as Executive Vice President, General Counsel, Chief Compliance and Risk Management Officer and Secretary of General Mills and would retire from these roles in February 2015. "We are pleased to welcome Rick to the Express Scripts Board of Directors, and we appreciate the wealth of expertise and experience he will bring to us," said George Paz, Chairman and CEO of Express Scripts. The full research reports on Express Scripts are available to download free of charge at:

http://www.analystsreview.com/Sep-23-2014/ESRX/report.pdf

--
Stryker Corporation Research Reports
On September 8, 2014, Stryker Corporation (Stryker) announced that it will release its Q3 2014 operating results on Thursday, October 16, 2014 at 4:00 p.m. ET. The Company added that it will also host a conference call on the same day at 4:30 p.m. ET to discuss the results and provide an operational update. Stryker informed that a live webcast of the call and archive of the same for 90 days will be accessible via its website. The full research reports on Stryker are available to download free of charge at:

http://www.analystsreview.com/Sep-23-2014/SYK/report.pdf

--
Shire plc. Research Reports
On September 15, 2014, Shire plc (Shire) announced that the Company's supplemental New Drug Application (sNDA) for Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) has been accepted for filing with priority review by the US Food and Drug Administration (FDA) as a treatment for adults with binge eating disorder (BED). Shire added that FDA's decision is expected in February 2015, based on the anticipated Prescription Drug User Fee Act (PDUFA) action date. "The decision from the FDA to accept our filing for priority review not only marks progress in the development of Vyvanse for adults with BED, but underscores this is an area of unmet medical need as there are currently no approved pharmacologic options for these patients," said Phil Vickers, PhD, Head of Research and Development, Shire. The full research reports on Shire are available to download free of charge at:

http://www.analystsreview.com/Sep-23-2014/SHPG/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review